메뉴 건너뛰기




Volumn 53, Issue 4, 2014, Pages 305-325

Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: Focus on the pharmacokinetic targets

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; AXITINIB; CAPECITABINE; CRIZOTINIB; DASATINIB; ERLOTINIB; GEFITINIB; GEMCITABINE; IMATINIB; LAPATINIB; NILOTINIB; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TRASTUZUMAB; VANDETANIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

EID: 84899061817     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-014-0137-2     Document Type: Article
Times cited : (211)

References (165)
  • 1
    • 7444231093 scopus 로고    scopus 로고
    • Practical guidelines to interpret plasma concentrations of antiretroviral drugs
    • Kappelhoff BS, Crommentuyn KML, de Maat MMR, et al. Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin Pharmacokinet. 2004;43(13):845-53.
    • (2004) Clin Pharmacokinet , vol.43 , Issue.13 , pp. 845-853
    • Kappelhoff, B.S.1    Crommentuyn, K.M.L.2    De Maat, M.M.R.3
  • 2
    • 13244298666 scopus 로고    scopus 로고
    • Individualised cancer chemotherapy: Strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: A review
    • De Jonge ME, Huitema ADR, Schellens JHM, et al. Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review. Clin Pharmacokinet. 2005;44(2):147-73.
    • (2005) Clin Pharmacokinet , vol.44 , Issue.2 , pp. 147-173
    • De Jonge, M.E.1    Huitema, A.D.R.2    Schellens, J.H.M.3
  • 3
    • 84949176834 scopus 로고    scopus 로고
    • Therapeutic drug monitoring of targeted anticancer therapy. Tyrosine kinase inhibitors and selective estrogen receptor modulators: A clinical pharmacology laboratory perspective
    • Q.A. Xu T.L. Madden (eds) Springer Boston
    • Decosterd L, Dahmane E, Neeman M, et al. Therapeutic drug monitoring of targeted anticancer therapy. Tyrosine kinase inhibitors and selective estrogen receptor modulators: a clinical pharmacology laboratory perspective. In: Xu QA, Madden TL, editors. LC-MS in drug bioanalysis. Boston: Springer; 2012. p. 197-250.
    • (2012) LC-MS in Drug Bioanalysis , pp. 197-250
    • Decosterd, L.1    Dahmane, E.2    Neeman, M.3
  • 4
    • 84869381780 scopus 로고    scopus 로고
    • Evidence for therapeutic drug monitoring of targeted anticancer therapies
    • Gao B, Yeap S, Clements A, et al. Evidence for therapeutic drug monitoring of targeted anticancer therapies. J Clin Oncol. 2012;30(32):4017-25.
    • (2012) J Clin Oncol , vol.30 , Issue.32 , pp. 4017-4025
    • Gao, B.1    Yeap, S.2    Clements, A.3
  • 5
    • 79953004875 scopus 로고    scopus 로고
    • Therapeutic drug monitoring in oncology: Does it have a future?
    • McMahon G, O'Connor R. Therapeutic drug monitoring in oncology: does it have a future? Bioanalysis. 2009;1(3):507-11.
    • (2009) Bioanalysis , vol.1 , Issue.3 , pp. 507-511
    • McMahon, G.1    O'Connor, R.2
  • 6
    • 84874148548 scopus 로고    scopus 로고
    • Without therapeutic drug monitoring, there is no personalized cancer care
    • Beumer JH. Without therapeutic drug monitoring, there is no personalized cancer care. Clin Pharmacol Ther. 2013;93(3):228-30.
    • (2013) Clin Pharmacol Ther , vol.93 , Issue.3 , pp. 228-230
    • Beumer, J.H.1
  • 7
    • 33646135276 scopus 로고    scopus 로고
    • Tyrosine kinase - Role and significance in cancer
    • 1074718
    • Paul MK, Mukhopadhyay AK. Tyrosine kinase - role and significance in cancer. Int J Med Sci. 2004;1(2):101-15.
    • (2004) Int J Med Sci , vol.1 , Issue.2 , pp. 101-115
    • Paul, M.K.1    Mukhopadhyay, A.K.2
  • 8
    • 0008348082 scopus 로고    scopus 로고
    • European Medicines Agency (EMA) Accessed 8 Jan 2014
    • European Medicines Agency (EMA). European Public Assessment Reports. http://www.ema.europa.eu/ema. Accessed 8 Jan 2014.
    • European Public Assessment Reports
  • 9
    • 84899119611 scopus 로고    scopus 로고
    • US Food and Drug Administration. http://www.fda.gov. Accessed 8 Jan 2014
    • US Food and Drug Administration. http://www.fda.gov. Accessed 8 Jan 2014.
  • 10
    • 79953077853 scopus 로고    scopus 로고
    • Moving towards dose individualization of tyrosine kinase inhibitors
    • Klümpen H-J, Samer CF, Mathijssen RHJ, et al. Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treat Rev. 2011;37(4):251-60.
    • (2011) Cancer Treat Rev , vol.37 , Issue.4 , pp. 251-260
    • Klümpen, H.-J.1    Samer, C.F.2    Mathijssen, R.H.J.3
  • 11
    • 70449704111 scopus 로고    scopus 로고
    • Clinical pharmacokinetics of tyrosine kinase inhibitors
    • Van Erp NP, Gelderblom H, Guchelaar H-J. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009;35(8):692-706.
    • (2009) Cancer Treat Rev , vol.35 , Issue.8 , pp. 692-706
    • Van Erp, N.P.1    Gelderblom, H.2    Guchelaar, H.-J.3
  • 12
    • 84899067370 scopus 로고    scopus 로고
    • Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care
    • Epub 2013 Dec 3
    • Lankheet NAG, Knapen LM, Schellens JHM, et al. Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care. Ther Drug Monit. Epub 2013 Dec 3.
    • Ther Drug Monit
    • Nag, L.1    Knapen, L.M.2    Schellens, J.H.M.3
  • 13
    • 84885021526 scopus 로고    scopus 로고
    • Clinical pharmacokinetics of tyrosine kinase inhibitors: Implications for therapeutic drug monitoring
    • Josephs DH, Fisher DS, Spicer J, et al. Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring. Ther Drug Monit. 2013;35(5):562-87.
    • (2013) Ther Drug Monit , vol.35 , Issue.5 , pp. 562-587
    • Josephs, D.H.1    Fisher, D.S.2    Spicer, J.3
  • 15
    • 84876993943 scopus 로고    scopus 로고
    • Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib
    • Rini BI, de La Motte Rouge T, Harzstark AL, et al. Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib. Clin Genitourin Cancer. 2013;11(2):107-14.
    • (2013) Clin Genitourin Cancer , vol.11 , Issue.2 , pp. 107-114
    • Rini, B.I.1    De La Motte Rouge, T.2    Harzstark, A.L.3
  • 16
    • 77649125649 scopus 로고    scopus 로고
    • Diastolic blood pressure (dBP) and pharmacokinetics (PK) as predictors of axitinib efficacy in metastatic renal cell cancer (mRCC) [abstract no. 5045]
    • Rixe O, Dutcher J, Motzer R, et al. Diastolic blood pressure (dBP) and pharmacokinetics (PK) as predictors of axitinib efficacy in metastatic renal cell cancer (mRCC) [abstract no. 5045]. J Clin Oncol. 2009;27:15S.
    • (2009) J Clin Oncol , vol.27
    • Rixe, O.1    Dutcher, J.2    Motzer, R.3
  • 17
    • 84880157519 scopus 로고    scopus 로고
    • Axitinib in metastatic renal cell carcinoma: Results of a pharmacokinetic and pharmacodynamic analysis
    • Rini BI, Garrett M, Poland B, et al. Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol. 2013;53(5):491-504.
    • (2013) J Clin Pharmacol , vol.53 , Issue.5 , pp. 491-504
    • Rini, B.I.1    Garrett, M.2    Poland, B.3
  • 18
    • 79957909038 scopus 로고    scopus 로고
    • Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors
    • Rini BI, Schiller JH, Fruehauf JP, et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res. 2011;17(11):3841-9.
    • (2011) Clin Cancer Res , vol.17 , Issue.11 , pp. 3841-3849
    • Rini, B.I.1    Schiller, J.H.2    Fruehauf, J.P.3
  • 19
    • 84884949662 scopus 로고    scopus 로고
    • Axitinib with or without dose titration for first-line metastatic renal cell carcinoma (mRCC): Unblinded results from a randomized phase II study [abstract no. LBA349]
    • Rini BI, Gruenwald V, Fishman MN, et al. Axitinib with or without dose titration for first-line metastatic renal cell carcinoma (mRCC): unblinded results from a randomized phase II study [abstract no. LBA349]. J Clin Oncol. 2013;31(suppl 6).
    • (2013) J Clin Oncol. , vol.31 , Issue.SUPPL. 6
    • Rini, B.I.1    Gruenwald, V.2    Fishman, M.N.3
  • 20
    • 84886719423 scopus 로고    scopus 로고
    • Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: A randomised double-blind phase 2 trial
    • Rini BI, Melichar B, Ueda T, et al. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol. 2013;14(12):1233-42.
    • (2013) Lancet Oncol , vol.14 , Issue.12 , pp. 1233-1242
    • Rini, B.I.1    Melichar, B.2    Ueda, T.3
  • 21
    • 84857465780 scopus 로고    scopus 로고
    • Maximizing clinical outcomes with axitinib therapy in advanced renal cell carcinoma through proactive side-effect management
    • Wood LS, Gornell S, Rini BI. Maximizing clinical outcomes with axitinib therapy in advanced renal cell carcinoma through proactive side-effect management. Community Oncol. 2012;9(2):46-55.
    • (2012) Community Oncol , vol.9 , Issue.2 , pp. 46-55
    • Wood, L.S.1    Gornell, S.2    Rini, B.I.3
  • 22
    • 79952773320 scopus 로고    scopus 로고
    • Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients [abstract no. 2596]
    • Tan W, Wilner KD, Bang Y, et al. Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients [abstract no. 2596]. J Clin Oncol. 2010;28(15 suppl).
    • (2010) J Clin Oncol. , vol.28 , Issue.15 SUPPL.
    • Tan, W.1    Wilner, K.D.2    Bang, Y.3
  • 23
    • 37549059613 scopus 로고    scopus 로고
    • Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
    • Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007;6(12 Pt 1):3314-22.
    • (2007) Mol Cancer Ther , vol.6 , Issue.12 , pp. 3314-3322
    • Christensen, J.G.1    Zou, H.Y.2    Arango, M.E.3
  • 24
    • 79957487193 scopus 로고    scopus 로고
    • CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib
    • Costa DB, Kobayashi S. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011;29(15):2011-3.
    • (2011) J Clin Oncol , vol.29 , Issue.15 , pp. 2011-2013
    • Costa, D.B.1    Kobayashi, S.2
  • 25
    • 84863116231 scopus 로고    scopus 로고
    • Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models
    • Yamazaki S, Vicini P, Shen Z, et al. Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models. J Pharmacol Exp Ther. 2012;340(3):549-57.
    • (2012) J Pharmacol Exp Ther , vol.340 , Issue.3 , pp. 549-557
    • Yamazaki, S.1    Vicini, P.2    Shen, Z.3
  • 26
    • 84877018103 scopus 로고    scopus 로고
    • Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: A case study of anticancer drug, crizotinib
    • 3675733
    • Yamazaki S. Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib. AAPS J. 2013;15(2):354-66.
    • (2013) AAPS J , vol.15 , Issue.2 , pp. 354-366
    • Yamazaki, S.1
  • 27
    • 84873974299 scopus 로고    scopus 로고
    • Crizotinib: A new treatment option for ALK-positive non-small cell lung cancer
    • O'Bryant CL, Wenger SD, Kim M, et al. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer. Ann Pharmacother. 2013;47(2):189-97.
    • (2013) Ann Pharmacother , vol.47 , Issue.2 , pp. 189-197
    • O'Bryant, C.L.1    Wenger, S.D.2    Kim, M.3
  • 28
    • 77955174967 scopus 로고    scopus 로고
    • Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC) [abstract no. 3]
    • Bang Y, Kwak E, Shaw A, et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC) [abstract no. 3]. J Clin Oncol. 2010;28(18 suppl).
    • (2010) J Clin Oncol. , vol.28 , Issue.18 SUPPL.
    • Bang, Y.1    Kwak, E.2    Shaw, A.3
  • 29
    • 78649281412 scopus 로고    scopus 로고
    • Activity of crizotinib in patients with non-small cell lung cancer
    • Abraham J. Activity of crizotinib in patients with non-small cell lung cancer. Commun Oncol. 2010;7(10):443-4.
    • (2010) Commun Oncol , vol.7 , Issue.10 , pp. 443-444
    • Abraham, J.1
  • 30
    • 78049425319 scopus 로고    scopus 로고
    • Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
    • 3014291
    • Kwak EL, Bang YJ, Camidge R, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693-703.
    • (2010) N Engl J Med , vol.363 , Issue.18 , pp. 1693-1703
    • Kwak, E.L.1    Bang, Y.J.2    Camidge, R.3
  • 31
    • 79955036989 scopus 로고    scopus 로고
    • Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS
    • Bouchet S, Chauzit E, Ducint D, et al. Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS. Clin Chim Acta. 2011;412(11-12):1060-7.
    • (2011) Clin Chim Acta , vol.412 , Issue.11-12 , pp. 1060-1067
    • Bouchet, S.1    Chauzit, E.2    Ducint, D.3
  • 32
    • 84878999947 scopus 로고    scopus 로고
    • Differential effects of dosing regimen on the safety and efficacy of dasatinib: Retrospective exposure-response analysis of a phase III study
    • Wang X, Roy A, Hochhaus A, et al. Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a phase III study. Clin Pharmacol Adv Appl. 2013;5:85-97.
    • (2013) Clin Pharmacol Adv Appl , vol.5 , pp. 85-97
    • Wang, X.1    Roy, A.2    Hochhaus, A.3
  • 33
    • 81455139201 scopus 로고    scopus 로고
    • A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients
    • Pirro E, De Francia S, De Martino F, et al. A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. J Chromatogr Sci. 2011;49(10):753-7.
    • (2011) J Chromatogr Sci , vol.49 , Issue.10 , pp. 753-757
    • Pirro, E.1    De Francia, S.2    De Martino, F.3
  • 34
    • 33645221739 scopus 로고    scopus 로고
    • Dasatinib (BMS-354825): A multitargeted kinase inhibitor with activity against multiple myeloma
    • Deng Q, Mitsiades N, Negri J, et al. Dasatinib (BMS-354825): a multitargeted kinase inhibitor with activity against multiple myeloma. Blood (ASH Annual Meeting Abstracts). 2005;106:Abstract 1571.
    • (2005) Blood (ASH Annual Meeting Abstracts). , vol.106 , pp. 1571
    • Deng, Q.1    Mitsiades, N.2    Negri, J.3
  • 35
    • 43949122895 scopus 로고    scopus 로고
    • Potent transient inhibition of BCR-ABL by dasatinib leads to complete cytogenetic remissions in patients with chronic myeloid leukemia: Implications for patient management and drug development
    • Shah NP, Nicoll JM, Bleickardt E, et al. Potent transient inhibition of BCR-ABL by dasatinib leads to complete cytogenetic remissions in patients with chronic myeloid leukemia: implications for patient management and drug development. Blood (ASH Annual Meeting Abstracts). 2006;108:Abstract 2166.
    • (2006) Blood (ASH Annual Meeting Abstracts). , vol.108 , pp. 2166
    • Shah, N.P.1    Nicoll, J.M.2    Bleickardt, E.3
  • 36
    • 33845723163 scopus 로고    scopus 로고
    • Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure
    • Luo FR, Yang Z, Camuso A, et al. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res. 2006;12(23):7180-6.
    • (2006) Clin Cancer Res , vol.12 , Issue.23 , pp. 7180-7186
    • Luo, F.R.1    Yang, Z.2    Camuso, A.3
  • 37
    • 38949134552 scopus 로고    scopus 로고
    • Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate
    • Brave M, Goodman V, Kaminskas E, et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res. 2008;14(2):352-9.
    • (2008) Clin Cancer Res , vol.14 , Issue.2 , pp. 352-359
    • Brave, M.1    Goodman, V.2    Kaminskas, E.3
  • 38
    • 55949102580 scopus 로고    scopus 로고
    • Dasatinib pharmacokinetics and exposure-response (E-R): Relationship to safety and efficacy in patients (pts) with chronic myeloid leukemia (CML) [abstract no. 3590]
    • Wang X, Hochhaus A, Kantarjian HM, et al. Dasatinib pharmacokinetics and exposure-response (E-R): Relationship to safety and efficacy in patients (pts) with chronic myeloid leukemia (CML) [abstract no. 3590]. J Clin Oncol. 2008;26(15 suppl).
    • (2008) J Clin Oncol. , vol.26 , Issue.15 SUPPL.
    • Wang, X.1    Hochhaus, A.2    Kantarjian, H.M.3
  • 39
    • 84894089305 scopus 로고    scopus 로고
    • Pharmacologic monitoring of dasatinib as first line therapy in newly diagnosed chronic phase chronic myelogenous leukemia (CP-CML) identifies patients at higher risk of pleural effusion: A sub-analysis of the OPTIM-Dasatinib Trial
    • Rousselot P, Mollica L, Etienne G, et al. Pharmacologic monitoring of dasatinib as first line therapy in newly diagnosed chronic phase chronic myelogenous leukemia (CP-CML) identifies patients at higher risk of pleural effusion: a sub-analysis of the OPTIM-Dasatinib Trial. Blood (ASH Annual Meeting Abstracts). 2012;120:Abstract 3770.
    • (2012) Blood (ASH Annual Meeting Abstracts) , vol.120 , pp. 3770
    • Rousselot, P.1    Mollica, L.2    Etienne, G.3
  • 40
    • 80053278339 scopus 로고    scopus 로고
    • Erlotinib "dosing-to-rash": A phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer
    • 3185947
    • Mita AC, Papadopoulos K, de Jonge MJA, et al. Erlotinib "dosing-to-rash": a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer. Br J Cancer. 2011;105(7):938-44.
    • (2011) Br J Cancer , vol.105 , Issue.7 , pp. 938-944
    • Mita, A.C.1    Papadopoulos, K.2    De Jonge, M.J.A.3
  • 41
    • 4344646459 scopus 로고    scopus 로고
    • Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer
    • Pérez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2004;22(16):3238-47.
    • (2004) J Clin Oncol , vol.22 , Issue.16 , pp. 3238-3247
    • Pérez-Soler, R.1    Chachoua, A.2    Hammond, L.A.3
  • 42
    • 68749095215 scopus 로고    scopus 로고
    • Population pharmacokinetics of erlotinib and its pharmacokinetic/ pharmacodynamic relationships in head and neck squamous cell carcinoma
    • Thomas F, Rochaix P, White-Koning M, et al. Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma. Eur J Cancer. 2009;45(13):2316-23.
    • (2009) Eur J Cancer , vol.45 , Issue.13 , pp. 2316-2323
    • Thomas, F.1    Rochaix, P.2    White-Koning, M.3
  • 43
    • 34047190928 scopus 로고    scopus 로고
    • Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer
    • Calvo E, Malik SN, Siu LL, et al. Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer. Ann Oncol. 2007;18(4):761-7.
    • (2007) Ann Oncol , vol.18 , Issue.4 , pp. 761-767
    • Calvo, E.1    Malik, S.N.2    Siu, L.L.3
  • 44
    • 1842772526 scopus 로고    scopus 로고
    • Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck
    • Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004;22(1):77-85.
    • (2004) J Clin Oncol , vol.22 , Issue.1 , pp. 77-85
    • Soulieres, D.1    Senzer, N.N.2    Vokes, E.E.3
  • 45
    • 77954425045 scopus 로고    scopus 로고
    • Erlotinib at a dose of 25 mg daily for non-small-cell lung cancers with EGFR mutations
    • 2893286
    • Yeo W, Riely GJ, Yeap BY, et al. Erlotinib at a dose of 25 mg daily for non-small-cell lung cancers with EGFR mutations. J Thorac Oncol. 2010;5(7):1048-53.
    • (2010) J Thorac Oncol , vol.5 , Issue.7 , pp. 1048-1053
    • Yeo, W.1    Riely, G.J.2    Yeap, B.Y.3
  • 46
    • 84899097625 scopus 로고    scopus 로고
    • Accessed 20 Mar 2013
    • Erlotinib EMA scientific discussion. http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Scientific-Discussion/human/000618/WC500033991.pdf. Accessed 20 Mar 2013.
    • Erlotinib EMA Scientific Discussion
  • 47
    • 0030774045 scopus 로고    scopus 로고
    • Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase
    • Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997;57(21):4838-48.
    • (1997) Cancer Res , vol.57 , Issue.21 , pp. 4838-4848
    • Moyer, J.D.1    Barbacci, E.G.2    Iwata, K.K.3
  • 48
    • 0032695910 scopus 로고    scopus 로고
    • Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice
    • Pollack VA, Savage DM, Baker DA, et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther. 1999;291(2):739-48.
    • (1999) J Pharmacol Exp Ther , vol.291 , Issue.2 , pp. 739-748
    • Pollack, V.A.1    Savage, D.M.2    Baker, D.A.3
  • 49
    • 0035398631 scopus 로고    scopus 로고
    • Phase i and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
    • Hidalgo M, Siu LL, Nemunaitis J. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 2001;19(13):3267-79.
    • (2001) J Clin Oncol , vol.19 , Issue.13 , pp. 3267-3279
    • Hidalgo, M.1    Siu, L.L.2    Nemunaitis, J.3
  • 50
    • 0035215722 scopus 로고    scopus 로고
    • Selected novel anticancer treatments targeting cell signaling proteins
    • Elsayed YA, Sausville EA. Selected novel anticancer treatments targeting cell signaling proteins. Oncologist. 2001;6(6):517-37.
    • (2001) Oncologist , vol.6 , Issue.6 , pp. 517-537
    • Elsayed, Y.A.1    Sausville, E.A.2
  • 51
    • 10944226719 scopus 로고    scopus 로고
    • Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection
    • Zhang W, Siu LL, Moore MJ, et al. Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection. J Chromatogr B. 2005;814(1):143-7.
    • (2005) J Chromatogr B , vol.814 , Issue.1 , pp. 143-147
    • Zhang, W.1    Siu, L.L.2    Moore, M.J.3
  • 52
    • 34250208469 scopus 로고    scopus 로고
    • Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study
    • Siu LL, Soulieres D, Chen EX, et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol. 2007;25(16):2178-83.
    • (2007) J Clin Oncol , vol.25 , Issue.16 , pp. 2178-2183
    • Siu, L.L.1    Soulieres, D.2    Chen, E.X.3
  • 53
    • 39749089941 scopus 로고    scopus 로고
    • A phase i and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies
    • Chiorean EG, Porter JM, Foster AE, et al. A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies. Clin Cancer Res. 2008;14(4):1131-7.
    • (2008) Clin Cancer Res , vol.14 , Issue.4 , pp. 1131-1137
    • Chiorean, E.G.1    Porter, J.M.2    Foster, A.E.3
  • 54
    • 0037674062 scopus 로고    scopus 로고
    • Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck
    • Cohen EEW, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003;21(10):1980-7.
    • (2003) J Clin Oncol , vol.21 , Issue.10 , pp. 1980-1987
    • Cohen, E.E.W.1    Rosen, F.2    Stadler, W.M.3
  • 55
    • 38549167111 scopus 로고    scopus 로고
    • Clinical research of EGFR inhibitors and related dermatological toxicities
    • Perez-Soler R, van Cutsem E. Clinical research of EGFR inhibitors and related dermatological toxicities. Oncology (Williston Park). 2007;21(11 suppl 5):10-6.
    • (2007) Oncology (Williston Park) , vol.21 , Issue.11 SUPPL. 5 , pp. 10-16
    • Perez-Soler, R.1    Van Cutsem, E.2
  • 56
    • 84892893614 scopus 로고    scopus 로고
    • Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC)
    • Tiseo M, Andreoli R, Gelsomino F, et al. Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer. 2014;83:265-71.
    • (2014) Lung Cancer , vol.83 , pp. 265-271
    • Tiseo, M.1    Andreoli, R.2    Gelsomino, F.3
  • 57
    • 33746678595 scopus 로고    scopus 로고
    • Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer
    • Lu J-F, Eppler SM, Wolf J, et al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther. 2006;80(2):136-45.
    • (2006) Clin Pharmacol Ther , vol.80 , Issue.2 , pp. 136-145
    • Lu, J.-F.1    Eppler, S.M.2    Wolf, J.3
  • 58
    • 80052435929 scopus 로고    scopus 로고
    • The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib
    • Zhao Y-Y, Li S, Zhang Y, et al. The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib. Med Oncol. 2011;28(3):697-702.
    • (2011) Med Oncol , vol.28 , Issue.3 , pp. 697-702
    • Zhao, Y.-Y.1    Li, S.2    Zhang, Y.3
  • 59
    • 77956264432 scopus 로고    scopus 로고
    • Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer
    • Nakamura Y, Sano K, Soda H. Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer. J Thorac Oncol. 2010;5(9):1404-9.
    • (2010) J Thorac Oncol , vol.5 , Issue.9 , pp. 1404-1409
    • Nakamura, Y.1    Sano, K.2    Soda, H.3
  • 60
    • 20044370274 scopus 로고    scopus 로고
    • Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer
    • Mohamed MK, Ramalingam S, Lin Y, et al. Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. Ann Oncol. 2005;16(5):780-5.
    • (2005) Ann Oncol , vol.16 , Issue.5 , pp. 780-785
    • Mohamed, M.K.1    Ramalingam, S.2    Lin, Y.3
  • 61
    • 33646381931 scopus 로고    scopus 로고
    • Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126
    • West HL, Franklin WA, McCoy J, et al. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol. 2006;24(12):1807-13.
    • (2006) J Clin Oncol , vol.24 , Issue.12 , pp. 1807-1813
    • West, H.L.1    Franklin, W.A.2    McCoy, J.3
  • 62
    • 84876565639 scopus 로고    scopus 로고
    • Skin rash by gefitinib is a sign of favorable outcomes for patients of advanced lung adenocarcinoma in Japanese patients
    • 3569587
    • Sugiura Y, Nemoto E, Kawai O, et al. Skin rash by gefitinib is a sign of favorable outcomes for patients of advanced lung adenocarcinoma in Japanese patients. Springerplus. 2013;2(1):22.
    • (2013) Springerplus , vol.2 , Issue.1 , pp. 22
    • Sugiura, Y.1    Nemoto, E.2    Kawai, O.3
  • 63
    • 84866144502 scopus 로고    scopus 로고
    • Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: A literature-based meta-analysis of 24 trials
    • Petrelli F, Borgonovo K, Cabiddu M, et al. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer. 2012;78(1):8-15.
    • (2012) Lung Cancer , vol.78 , Issue.1 , pp. 8-15
    • Petrelli, F.1    Borgonovo, K.2    Cabiddu, M.3
  • 64
    • 84865184491 scopus 로고    scopus 로고
    • Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck
    • Perez CA, Song H, Raez LE, et al. Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2012;48(9):887-92.
    • (2012) Oral Oncol , vol.48 , Issue.9 , pp. 887-892
    • Perez, C.A.1    Song, H.2    Raez, L.E.3
  • 65
    • 34147174980 scopus 로고    scopus 로고
    • Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
    • Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2007;109(8):3496-9.
    • (2007) Blood , vol.109 , Issue.8 , pp. 3496-3499
    • Picard, S.1    Titier, K.2    Etienne, G.3
  • 66
    • 43249083718 scopus 로고    scopus 로고
    • Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: A subanalysis of the IRIS study
    • Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111(8):4022-8.
    • (2008) Blood , vol.111 , Issue.8 , pp. 4022-4028
    • Larson, R.A.1    Druker, B.J.2    Guilhot, F.3
  • 67
    • 78449312021 scopus 로고    scopus 로고
    • Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic-phase chronic myeloid leukemia
    • Takahashi N, Wakita H, Miura M, et al. Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic-phase chronic myeloid leukemia. Clin Pharmacol Ther. 2010;88(6):809-13.
    • (2010) Clin Pharmacol Ther , vol.88 , Issue.6 , pp. 809-813
    • Takahashi, N.1    Wakita, H.2    Miura, M.3
  • 68
    • 84870931711 scopus 로고    scopus 로고
    • Imatinib plasma trough levels in chronic myeloid leukaemia: Results of a multicentre study CSTI571AIL11TGLIVEC
    • Koren-Michowitz M, Volchek Y, Naparstek E, et al. Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC. Hematol Oncol. 2012;30(4):200-5.
    • (2012) Hematol Oncol , vol.30 , Issue.4 , pp. 200-205
    • Koren-Michowitz, M.1    Volchek, Y.2    Naparstek, E.3
  • 69
    • 77952467377 scopus 로고    scopus 로고
    • Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib
    • Marin D, Bazeos A, Mahon F-X, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381-8.
    • (2010) J Clin Oncol , vol.28 , Issue.14 , pp. 2381-2388
    • Marin, D.1    Bazeos, A.2    Mahon, F.-X.3
  • 70
    • 77953952853 scopus 로고    scopus 로고
    • Integrating pharmacogenetics and therapeutic drug monitoring: Optimal dosing of imatinib as a case-example
    • Li-Wan-Po A, Farndon P, Craddock C, et al. Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example. Eur J Clin Pharmacol. 2010;66(4):369-74.
    • (2010) Eur J Clin Pharmacol , vol.66 , Issue.4 , pp. 369-374
    • Li-Wan-Po, A.1    Farndon, P.2    Craddock, C.3
  • 71
    • 68849113721 scopus 로고    scopus 로고
    • Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: Comparing plasma levels of responders and non-responders
    • Singh N, Kumar L, Meena R, et al. Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders. Eur J Clin Pharmacol. 2009;65(6):545-9.
    • (2009) Eur J Clin Pharmacol , vol.65 , Issue.6 , pp. 545-549
    • Singh, N.1    Kumar, L.2    Meena, R.3
  • 72
    • 78149357619 scopus 로고    scopus 로고
    • Relationship of serum imatinib trough level and response in CML patients: Long term follow-up
    • Awidi A, Ayed AO, Bsoul N, et al. Relationship of serum imatinib trough level and response in CML patients: long term follow-up. Leuk Res. 2010;34(12):1573-5.
    • (2010) Leuk Res , vol.34 , Issue.12 , pp. 1573-1575
    • Awidi, A.1    Ayed, A.O.2    Bsoul, N.3
  • 73
    • 67650306170 scopus 로고    scopus 로고
    • Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors
    • Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol. 2009;27(19):3141-7.
    • (2009) J Clin Oncol , vol.27 , Issue.19 , pp. 3141-3147
    • Demetri, G.D.1    Wang, Y.2    Wehrle, E.3
  • 74
    • 77950369782 scopus 로고    scopus 로고
    • Imatinib plasma levels: Correlation with clinical benefit in GIST patients
    • 2853086
    • Widmer N, Decosterd L, Csajka C, et al. Imatinib plasma levels: correlation with clinical benefit in GIST patients. Br J Cancer. 2010;102(7):1198-9.
    • (2010) Br J Cancer , vol.102 , Issue.7 , pp. 1198-1199
    • Widmer, N.1    Decosterd, L.2    Csajka, C.3
  • 75
    • 84875078162 scopus 로고    scopus 로고
    • Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours
    • Haouala A, Widmer N, Guidi M, et al. Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours. Br J Clin Pharmacol. 2013;75(4):1007-18.
    • (2013) Br J Clin Pharmacol , vol.75 , Issue.4 , pp. 1007-1018
    • Haouala, A.1    Widmer, N.2    Guidi, M.3
  • 76
    • 84874093024 scopus 로고    scopus 로고
    • Long-term prospective population PK study in GIST patients [letter]
    • Chatelut E, Gandia P, Gotta V, et al. Long-term prospective population PK study in GIST patients [letter]. Clin Cancer Res. 2013;19(4):949.
    • (2013) Clin Cancer Res , vol.19 , Issue.4 , pp. 949
    • Chatelut, E.1    Gandia, P.2    Gotta, V.3
  • 77
    • 84867521054 scopus 로고    scopus 로고
    • A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients
    • Eechoute K, Fransson MN, Reyners AK, et al. A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res. 2012;18(20):5780-7.
    • (2012) Clin Cancer Res , vol.18 , Issue.20 , pp. 5780-5787
    • Eechoute, K.1    Fransson, M.N.2    Reyners, A.K.3
  • 78
    • 33750735723 scopus 로고    scopus 로고
    • Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors
    • Delbaldo C, Chatelut E, Ré M, et al. Pharmacokinetic- pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res. 2006;12(20 Pt 1):6073-8.
    • (2006) Clin Cancer Res , vol.12 , Issue.20 PART 1 , pp. 6073-6078
    • Delbaldo, C.1    Chatelut, E.2    Ré, M.3
  • 79
    • 77953723830 scopus 로고    scopus 로고
    • 24 Months update of the TOPS study: A phase III, randomized, open-label study of 400 mg/d (SD-IM) versus 800 mg/d (HD-IM) of imatinib mesylate (IM) in patients (Pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP)
    • Baccarani M, Druker B, Cortes-Franco J, et al. 24 Months update of the TOPS study: a phase III, randomized, open-label study of 400 mg/d (SD-IM) versus 800 mg/d (HD-IM) of imatinib mesylate (IM) in patients (Pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP). Blood (ASH Annual Meeting Abstracts). 2009;114:Abstract 337.
    • (2009) Blood (ASH Annual Meeting Abstracts) , vol.114 , pp. 337
    • Baccarani, M.1    Druker, B.2    Cortes-Franco, J.3
  • 80
    • 84856109375 scopus 로고    scopus 로고
    • The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors
    • Teng JFT, Mabasa VH, Ensom MHH. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors. Ther Drug Monit. 2012;34(1):85-97.
    • (2012) Ther Drug Monit , vol.34 , Issue.1 , pp. 85-97
    • Teng, J.F.T.1    Mabasa, V.H.2    Ensom, M.H.H.3
  • 81
    • 34548830783 scopus 로고    scopus 로고
    • Therapeutic drug monitoring in CML patients on imatinib [letter]
    • (author reply 1701)
    • Blasdel C, Egorin MJ, Lagattuta TF, et al. Therapeutic drug monitoring in CML patients on imatinib [letter]. Blood. 2007;110(5):1699-701 (author reply 1701).
    • (2007) Blood. , vol.110 , Issue.5 , pp. 1699-1701
    • Blasdel, C.1    Egorin, M.J.2    Lagattuta, T.F.3
  • 84
    • 23944476155 scopus 로고    scopus 로고
    • Phase i safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
    • Burris HA III, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol. 2005;23(23):5305-13.
    • (2005) J Clin Oncol , vol.23 , Issue.23 , pp. 5305-5313
    • Burris III, H.A.1    Hurwitz, H.I.2    Dees, E.C.3
  • 85
    • 70350743116 scopus 로고    scopus 로고
    • A phase i and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies
    • 3232441
    • Burris HA III, Taylor CW, Jones SF, et al. A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clin Cancer Res. 2009;15(21):6702-8.
    • (2009) Clin Cancer Res , vol.15 , Issue.21 , pp. 6702-6708
    • Burris III, H.A.1    Taylor, C.W.2    Jones, S.F.3
  • 86
    • 84879341555 scopus 로고    scopus 로고
    • Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or intolerant CML from the East Japan CML Study Group (EJCML) trial: Evaluation of molecular responses by the BCR-ABL1 mutational status and plasma trough concentration
    • Takahashi N, Miura M, Kuroki J, et al. Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or intolerant CML from the East Japan CML Study Group (EJCML) trial: evaluation of molecular responses by the BCR-ABL1 mutational status and plasma trough concentration. Blood (ASH Annual Meeting Abstracts). 2012;120:Abstract 1360.
    • (2012) Blood (ASH Annual Meeting Abstracts). , vol.120 , pp. 1360
    • Takahashi, N.1    Miura, M.2    Kuroki, J.3
  • 87
    • 84864285497 scopus 로고    scopus 로고
    • Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase
    • Larson RA, Yin OQP, Hochhaus A, et al. Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. Eur J Clin Pharmacol. 2012;68(5):723-33.
    • (2012) Eur J Clin Pharmacol , vol.68 , Issue.5 , pp. 723-733
    • Larson, R.A.1    Yin, O.Q.P.2    Hochhaus, A.3
  • 88
    • 84876712497 scopus 로고    scopus 로고
    • Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia
    • Giles FJ, Yin OQP, Sallas WM, et al. Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia. Eur J Clin Pharmacol. 2013;69(4):813-23.
    • (2013) Eur J Clin Pharmacol , vol.69 , Issue.4 , pp. 813-823
    • Giles, F.J.1    Yin, O.Q.P.2    Sallas, W.M.3
  • 89
    • 34447322566 scopus 로고    scopus 로고
    • Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity
    • Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther. 2007;6(7):2012-21.
    • (2007) Mol Cancer Ther , vol.6 , Issue.7 , pp. 2012-2021
    • Kumar, R.1    Knick, V.B.2    Rudolph, S.K.3
  • 90
    • 67449164582 scopus 로고    scopus 로고
    • Phase i trial of pazopanib in patients with advanced cancer
    • Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res. 2009;15(12):4220-7.
    • (2009) Clin Cancer Res , vol.15 , Issue.12 , pp. 4220-4227
    • Hurwitz, H.I.1    Dowlati, A.2    Saini, S.3
  • 91
    • 84984538873 scopus 로고    scopus 로고
    • Phase i dose-finding study of pazopanib in hepatocellular carcinoma: Evaluation of early efficacy, pharmacokinetics, and pharmacodynamics
    • Yau T, Chen P-J, Chan P, et al. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics. Clin Cancer Res. 2011;17(21):6914-23.
    • (2011) Clin Cancer Res , vol.17 , Issue.21 , pp. 6914-6923
    • Yau, T.1    Chen, P.-J.2    Chan, P.3
  • 92
    • 78650413534 scopus 로고    scopus 로고
    • Relationship between exposure to pazopanib (P) and efficacy in patients (pts) with advanced renal cell carcinoma (mRCC) [abstract no. 3048]
    • Suttle B, Ball HA, Molimard M, et al. Relationship between exposure to pazopanib (P) and efficacy in patients (pts) with advanced renal cell carcinoma (mRCC) [abstract no. 3048]. J Clin Oncol. 2010;28(15 suppl).
    • (2010) J Clin Oncol. , vol.28 , Issue.15 SUPPL.
    • Suttle, B.1    Ball, H.A.2    Molimard, M.3
  • 93
    • 84898697355 scopus 로고    scopus 로고
    • Relationship between plasma pazopanib concentration and incidence of adverse events in renal cell carcinoma [abstract no. 345]
    • Lin Y, Ball HA, Suttle B, et al. Relationship between plasma pazopanib concentration and incidence of adverse events in renal cell carcinoma [abstract no. 345]. J Clin Oncol. 2011;29(7 suppl).
    • (2011) J Clin Oncol. , vol.29 , Issue.7 SUPPL.
    • Lin, Y.1    Ball, H.A.2    Suttle, B.3
  • 94
    • 84899071932 scopus 로고    scopus 로고
    • Pazopanib-EMA.
    • Pazopanib-EMA. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/001141/WC500094272.pdf. Accessed 21 Mar 2013.
  • 96
    • 34247857540 scopus 로고    scopus 로고
    • Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four phase i trials in patients with advanced refractory solid tumors
    • Strumberg D, Clark J, Awada A. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist. 2007;12(4):426-37.
    • (2007) Oncologist , vol.12 , Issue.4 , pp. 426-437
    • Strumberg, D.1    Clark, J.2    Awada, A.3
  • 97
    • 44449142019 scopus 로고    scopus 로고
    • Phase i and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors
    • Minami H, Kawada K, Ebi H, et al. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci. 2008;99(7):1492-8.
    • (2008) Cancer Sci , vol.99 , Issue.7 , pp. 1492-1498
    • Minami, H.1    Kawada, K.2    Ebi, H.3
  • 98
    • 67650293850 scopus 로고    scopus 로고
    • Phase II study of sorafenib in patients with metastatic or recurrent sarcomas
    • 2716936
    • Maki RG, D'Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009;27(19):3133-40.
    • (2009) J Clin Oncol , vol.27 , Issue.19 , pp. 3133-3140
    • Maki, R.G.1    D'Adamo, D.R.2    Keohan, M.L.3
  • 99
    • 84864626085 scopus 로고    scopus 로고
    • Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells
    • Kuckertz M, Patz M, Veldurthy A, et al. Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells. Onkologie. 2012;35(7-8):420-6.
    • (2012) Onkologie , vol.35 , Issue.7-8 , pp. 420-426
    • Kuckertz, M.1    Patz, M.2    Veldurthy, A.3
  • 100
    • 46449088111 scopus 로고    scopus 로고
    • Metabolism and disposition of dasatinib after oral administration to humans
    • Christopher L, Cui D, Wu C, et al. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos. 2008;36(7):1357-64.
    • (2008) Drug Metab Dispos , vol.36 , Issue.7 , pp. 1357-1364
    • Christopher, L.1    Cui, D.2    Wu, C.3
  • 101
    • 84865053668 scopus 로고    scopus 로고
    • Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: A preliminary study
    • 3418266
    • Boudou-Rouquette P, Narjoz C, Golmard JL, et al. Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study. PLoS One. 2012;7(8):e42875.
    • (2012) PLoS One , vol.7 , Issue.8 , pp. 42875
    • Boudou-Rouquette, P.1    Narjoz, C.2    Golmard, J.L.3
  • 102
    • 62949189153 scopus 로고    scopus 로고
    • Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice
    • Blanchet B, Billemont B, Cramard J, et al. Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. J Pharm Biomed Anal. 2009;49(4):1109-14.
    • (2009) J Pharm Biomed Anal , vol.49 , Issue.4 , pp. 1109-1114
    • Blanchet, B.1    Billemont, B.2    Cramard, J.3
  • 103
    • 84893332573 scopus 로고    scopus 로고
    • Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma
    • Fukudo M, Ito T, Mizuno T, et al. Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma. Clin Pharmacokinet. 2014;53:185-96.
    • (2014) Clin Pharmacokinet , vol.53 , pp. 185-196
    • Fukudo, M.1    Ito, T.2    Mizuno, T.3
  • 104
    • 84866673261 scopus 로고    scopus 로고
    • Sorafenib exposure decreases over time in patients with hepatocellular carcinoma
    • Arrondeau J, Mir O, Boudou-Rouquette P, et al. Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. Invest New Drugs. 2012;30(5):2046-9.
    • (2012) Invest New Drugs , vol.30 , Issue.5 , pp. 2046-2049
    • Arrondeau, J.1    Mir, O.2    Boudou-Rouquette, P.3
  • 105
    • 79954431917 scopus 로고    scopus 로고
    • A phase i open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer
    • 3064895
    • Tolcher AW, Appleman LJ, Shapiro GI, et al. A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol. 2011;67(4):751-64.
    • (2011) Cancer Chemother Pharmacol , vol.67 , Issue.4 , pp. 751-764
    • Tolcher, A.W.1    Appleman, L.J.2    Shapiro, G.I.3
  • 106
    • 77953033291 scopus 로고    scopus 로고
    • Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: Results of a pharmacokinetic/pharmacodynamic meta-analysis
    • Houk BE, Bello CL, Poland B, et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol. 2010;66(2):357-71.
    • (2010) Cancer Chemother Pharmacol , vol.66 , Issue.2 , pp. 357-371
    • Houk, B.E.1    Bello, C.L.2    Poland, B.3
  • 107
    • 84899098253 scopus 로고    scopus 로고
    • Sunitinib-EMA.
    • Sunitinib-EMA. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/000687/WC500057737.pdf. Accessed 16 Jul 2013.
  • 108
    • 33644847440 scopus 로고    scopus 로고
    • Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
    • Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24(1):25-35.
    • (2006) J Clin Oncol , vol.24 , Issue.1 , pp. 25-35
    • Faivre, S.1    Delbaldo, C.2    Vera, K.3
  • 109
    • 78549246206 scopus 로고    scopus 로고
    • Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate
    • Shirao K, Nishida T, Doi T, et al. Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate. Invest New Drugs. 2009;28(6):866-75.
    • (2009) Invest New Drugs , vol.28 , Issue.6 , pp. 866-875
    • Shirao, K.1    Nishida, T.2    Doi, T.3
  • 111
    • 78650874372 scopus 로고    scopus 로고
    • SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer
    • Abrams TJ, Lee LB, Murray LJ, et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003;2(5):471-8.
    • (2003) Mol Cancer Ther , vol.2 , Issue.5 , pp. 471-478
    • Abrams, T.J.1    Lee, L.B.2    Murray, L.J.3
  • 112
    • 12244301581 scopus 로고    scopus 로고
    • In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship
    • Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9(1):327-37.
    • (2003) Clin Cancer Res , vol.9 , Issue.1 , pp. 327-337
    • Mendel, D.B.1    Laird, A.D.2    Xin, X.3
  • 113
    • 9144274970 scopus 로고    scopus 로고
    • SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model
    • Murray LJ, Abrams TJ, Long KR, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis. 2003;20(8):757-66.
    • (2003) Clin Exp Metastasis , vol.20 , Issue.8 , pp. 757-766
    • Murray, L.J.1    Abrams, T.J.2    Long, K.R.3
  • 114
    • 2442669093 scopus 로고    scopus 로고
    • Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer
    • Abrams TJ, Murray LJ, Pesenti E, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther. 2003;2(10):1011-21.
    • (2003) Mol Cancer Ther , vol.2 , Issue.10 , pp. 1011-1021
    • Abrams, T.J.1    Murray, L.J.2    Pesenti, E.3
  • 115
    • 84899926811 scopus 로고    scopus 로고
    • Individual PK-guided sunitinib dosing: A feasibility study in patients with advanced solid tumors [abstract no. 2596]
    • Lankheet NAG, Kloth JSL, Gadellaa-van Hooijdonk CGM, et al. Individual PK-guided sunitinib dosing: A feasibility study in patients with advanced solid tumors [abstract no. 2596]. J Clin Oncol. 2012;30(15 suppl).
    • (2012) J Clin Oncol. , vol.30 , Issue.15 SUPPL.
    • Lankheet, N.A.G.1    Jsl, K.2    Gadellaa-Van Hooijdonk, C.G.M.3
  • 116
    • 67249147869 scopus 로고    scopus 로고
    • Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
    • George S, Blay JY, Casali PG, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer. 2009;45(11):1959-68.
    • (2009) Eur J Cancer , vol.45 , Issue.11 , pp. 1959-1968
    • George, S.1    Blay, J.Y.2    Casali, P.G.3
  • 117
    • 84861737588 scopus 로고    scopus 로고
    • Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors
    • Li J, Gao J, Hong J, et al. Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors. Future Oncol. 2012;8(5):617-24.
    • (2012) Future Oncol , vol.8 , Issue.5 , pp. 617-624
    • Li, J.1    Gao, J.2    Hong, J.3
  • 118
    • 0037102369 scopus 로고    scopus 로고
    • ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration
    • Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002;62(16):4645-55.
    • (2002) Cancer Res , vol.62 , Issue.16 , pp. 4645-4655
    • Wedge, S.R.1    Ogilvie, D.J.2    Dukes, M.3
  • 119
    • 0037115405 scopus 로고    scopus 로고
    • ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases
    • Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 2002;62(24):7284-90.
    • (2002) Cancer Res , vol.62 , Issue.24 , pp. 7284-7290
    • Carlomagno, F.1    Vitagliano, D.2    Guida, T.3
  • 120
    • 77956030786 scopus 로고    scopus 로고
    • Inhibition of mutated, activated BRAF in metastatic melanoma
    • 3724529
    • Flaherty KT, Puzanov I, Kim KB. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809-19.
    • (2010) N Engl J Med , vol.363 , Issue.9 , pp. 809-819
    • Flaherty, K.T.1    Puzanov, I.2    Kim, K.B.3
  • 122
    • 84863116743 scopus 로고    scopus 로고
    • Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
    • 3724515
    • Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707-14.
    • (2012) N Engl J Med , vol.366 , Issue.8 , pp. 707-714
    • Sosman, J.A.1    Kim, K.B.2    Schuchter, L.3
  • 123
    • 79959795786 scopus 로고    scopus 로고
    • Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    • 3549296
    • Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-16.
    • (2011) N Engl J Med , vol.364 , Issue.26 , pp. 2507-2516
    • Chapman, P.B.1    Hauschild, A.2    Robert, C.3
  • 124
    • 0037868167 scopus 로고    scopus 로고
    • Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer
    • Miller VA, Johnson DH, Krug LM, et al. Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer. J Clin Oncol. 2003;21(11):2094-100.
    • (2003) J Clin Oncol , vol.21 , Issue.11 , pp. 2094-2100
    • Miller, V.A.1    Johnson, D.H.2    Krug, L.M.3
  • 125
    • 1542608328 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of imatinib in a phase i trial with chronic myeloid leukemia patients
    • Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol. 2004;22(5):935-42.
    • (2004) J Clin Oncol , vol.22 , Issue.5 , pp. 935-942
    • Peng, B.1    Hayes, M.2    Resta, D.3
  • 126
    • 84859124139 scopus 로고    scopus 로고
    • Crizotinib: A novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond
    • 3232174
    • Ou S-HI. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des Devel Ther. 2011;5:471-85.
    • (2011) Drug des Devel Ther , vol.5 , pp. 471-485
    • Ou, S.-H.1
  • 127
    • 37849012740 scopus 로고    scopus 로고
    • Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals
    • Ling J, Fettner S, Lum BL, et al. Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. Anticancer Drugs. 2008;19(2):209-16.
    • (2008) Anticancer Drugs , vol.19 , Issue.2 , pp. 209-216
    • Ling, J.1    Fettner, S.2    Lum, B.L.3
  • 128
    • 84899058818 scopus 로고    scopus 로고
    • Gefitinib-EMA.
    • Gefitinib-EMA. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/001016/WC500036358.pdf. Accessed 10 Jun 2013.
  • 129
    • 84899064349 scopus 로고    scopus 로고
    • Imatinib-EMA.
    • Imatinib-EMA. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/000406/WC500022207.pdf. Accessed 26 Aug 2012.
  • 130
    • 62449338902 scopus 로고    scopus 로고
    • Effects of food on the relative bioavailability of lapatinib in cancer patients
    • Koch KM, Reddy NJ, Cohen RB, et al. Effects of food on the relative bioavailability of lapatinib in cancer patients. J Clin Oncol. 2009;27(8):1191-6.
    • (2009) J Clin Oncol , vol.27 , Issue.8 , pp. 1191-1196
    • Koch, K.M.1    Reddy, N.J.2    Cohen, R.B.3
  • 131
    • 84899082885 scopus 로고    scopus 로고
    • Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours
    • Epub 2013 Dec 19
    • Devriese LA, Koch KM, Mergui-Roelvink M, et al. Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours. Invest New Drugs. Epub 2013 Dec 19.
    • Invest New Drugs
    • Devriese, L.A.1    Koch, K.M.2    Mergui-Roelvink, M.3
  • 132
    • 84874182951 scopus 로고    scopus 로고
    • Playing Russian roulette with tyrosine kinase inhibitors
    • Szmulewitz RZ, Ratain MJ. Playing Russian roulette with tyrosine kinase inhibitors. Clin Pharmacol Ther. 2012;93(3):242-4.
    • (2012) Clin Pharmacol Ther , vol.93 , Issue.3 , pp. 242-244
    • Szmulewitz, R.Z.1    Ratain, M.J.2
  • 133
    • 84899113720 scopus 로고    scopus 로고
    • Nilotinib-EMA.
    • Nilotinib-EMA. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/000798/WC500034394.pdf. Accessed 14 Jun 0213.
  • 134
    • 84899046303 scopus 로고    scopus 로고
    • The effect of food on the intra-subject variability of the pharmacokinetics of ZD6474, a novel antiangiogenic agent, in healthy subjects [abstract no. 3167]
    • 14S Jul
    • Smith RP, Kennedy S, Robertson J, et al. The effect of food on the intra-subject variability of the pharmacokinetics of ZD6474, a novel antiangiogenic agent, in healthy subjects [abstract no. 3167]. J Clin Oncol 2004 ASCO Annu Meet Proc (Post-Meeting Ed);22(14S Jul 15 Suppl).
    • J Clin Oncol 2004 ASCO Annu Meet Proc (Post-Meeting Ed) , vol.22 , Issue.15 SUPPL.
    • Smith, R.P.1    Kennedy, S.2    Robertson, J.3
  • 135
    • 84899113216 scopus 로고    scopus 로고
    • Vemurafenib-EMA.
    • Vemurafenib-EMA. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/002409/WC500124317.pdf. Accessed 17 Jul 2013.
  • 136
    • 24944453855 scopus 로고    scopus 로고
    • Phase i trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacokinetic and clinical results
    • Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol. 2005;23(24):5474-83.
    • (2005) J Clin Oncol , vol.23 , Issue.24 , pp. 5474-5483
    • Rugo, H.S.1    Herbst, R.S.2    Liu, G.3
  • 137
    • 84899104067 scopus 로고    scopus 로고
    • Axitinib-EMA.
    • Axitinib-EMA. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/002406/WC500132188.pdf. Accessed 2 Jul 2013.
  • 138
    • 84864351085 scopus 로고    scopus 로고
    • Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: Results from phase i studies in Japanese patients
    • 3348450
    • Fujiwara Y, Kiyota N, Chayahara N, et al. Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients. Invest New Drugs. 2012;30(3):1055-64.
    • (2012) Invest New Drugs , vol.30 , Issue.3 , pp. 1055-1064
    • Fujiwara, Y.1    Kiyota, N.2    Chayahara, N.3
  • 139
    • 84867398104 scopus 로고    scopus 로고
    • Phase i trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours
    • 3494447
    • Kozloff MF, Martin LP, Krzakowski M, et al. Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. Br J Cancer. 2012;107(8):1277-85.
    • (2012) Br J Cancer , vol.107 , Issue.8 , pp. 1277-1285
    • Kozloff, M.F.1    Martin, L.P.2    Krzakowski, M.3
  • 140
    • 84867400512 scopus 로고    scopus 로고
    • Phase i study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours
    • 3494424
    • Martin LP, Kozloff MF, Herbst RS, et al. Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. Br J Cancer. 2012;107(8):1268-76.
    • (2012) Br J Cancer , vol.107 , Issue.8 , pp. 1268-1276
    • Martin, L.P.1    Kozloff, M.F.2    Herbst, R.S.3
  • 141
    • 77957269382 scopus 로고    scopus 로고
    • Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: A phase i study in Japanese patients
    • Mukohara T, Nakajima H, Mukai H, et al. Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients. Cancer Sci. 2010;101(4):963-8.
    • (2010) Cancer Sci , vol.101 , Issue.4 , pp. 963-968
    • Mukohara, T.1    Nakajima, H.2    Mukai, H.3
  • 142
    • 84899057651 scopus 로고    scopus 로고
    • Crizotinib-EMA.
    • Crizotinib-EMA. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/002489/WC500134759.pdf. Accessed 19 Nov 2013.
  • 143
    • 84055203408 scopus 로고    scopus 로고
    • Pharmacokinetics (PK) of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors [abstract no e13065]
    • Li C, Alvey C, Bello A, et al. Pharmacokinetics (PK) of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors [abstract no. e13065]. J Clin Oncol. 2011;29(15 suppl).
    • (2011) J Clin Oncol. , vol.29 , Issue.15 SUPPL.
    • Li, C.1    Alvey, C.2    Bello, A.3
  • 144
    • 84899079596 scopus 로고    scopus 로고
    • Dasatinib EMA.
    • Dasatinib EMA scientific discussion. http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Scientific-Discussion/human/000709/WC500056995.pdf. Accessed 9 Jul 2013.
  • 145
    • 79952095727 scopus 로고    scopus 로고
    • Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer
    • Okusaka T, Furuse J, Funakoshi A, et al. Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Cancer Sci. 2011;102(2):425-31.
    • (2011) Cancer Sci , vol.102 , Issue.2 , pp. 425-431
    • Okusaka, T.1    Furuse, J.2    Funakoshi, A.3
  • 146
    • 75749110539 scopus 로고    scopus 로고
    • A phase i trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas
    • 2940559
    • Raizer JJ, Abrey LE, Lassman AB, et al. A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol. 2010;12(1):87-94.
    • (2010) Neuro Oncol , vol.12 , Issue.1 , pp. 87-94
    • Raizer, J.J.1    Abrey, L.E.2    Lassman, A.B.3
  • 147
    • 33845680787 scopus 로고    scopus 로고
    • CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors
    • Li J, Karlsson MO, Brahmer J, et al. CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. J Natl Cancer Inst. 2006;98(23):1714-23.
    • (2006) J Natl Cancer Inst , vol.98 , Issue.23 , pp. 1714-1723
    • Li, J.1    Karlsson, M.O.2    Brahmer, J.3
  • 148
    • 82455175183 scopus 로고    scopus 로고
    • The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib
    • Horak J, White J, Harris AL, et al. The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib. Cancer Chemother Pharmacol. 2011;68(6):1485-95.
    • (2011) Cancer Chemother Pharmacol , vol.68 , Issue.6 , pp. 1485-1495
    • Horak, J.1    White, J.2    Harris, A.L.3
  • 149
    • 84873056956 scopus 로고    scopus 로고
    • Activity-based kinase profiling of approved tyrosine kinase inhibitors
    • Kitagawa D, Yokota K, Gouda M, et al. Activity-based kinase profiling of approved tyrosine kinase inhibitors. Genes Cells. 2013;18(2):110-22.
    • (2013) Genes Cells , vol.18 , Issue.2 , pp. 110-122
    • Kitagawa, D.1    Yokota, K.2    Gouda, M.3
  • 150
    • 67749101106 scopus 로고    scopus 로고
    • Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia
    • Kawaguchi T, Hamada A, Hirayama C, et al. Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia. Int J Hematol. 2009;89(5):642-8.
    • (2009) Int J Hematol , vol.89 , Issue.5 , pp. 642-648
    • Kawaguchi, T.1    Hamada, A.2    Hirayama, C.3
  • 151
    • 34547684260 scopus 로고    scopus 로고
    • Phase i pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors
    • Siegel-Lakhai WS, Beijnen JH, Vervenne WL, et al. Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors. Clin Cancer Res. 2007;13(15):4495-502.
    • (2007) Clin Cancer Res , vol.13 , Issue.15 , pp. 4495-4502
    • Siegel-Lakhai, W.S.1    Beijnen, J.H.2    Vervenne, W.L.3
  • 152
    • 51549101729 scopus 로고    scopus 로고
    • A phase i and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer
    • Chu QSC, Cianfrocca ME, Goldstein LJ, et al. A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer. Clin Cancer Res. 2008;14(14):4484-90.
    • (2008) Clin Cancer Res , vol.14 , Issue.14 , pp. 4484-4490
    • Chu, Q.S.C.1    Cianfrocca, M.E.2    Goldstein, L.J.3
  • 153
    • 82455175175 scopus 로고    scopus 로고
    • Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients
    • Rezai K, Urien S, Isambert N, et al. Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. Cancer Chemother Pharmacol. 2011;68(6):1529-36.
    • (2011) Cancer Chemother Pharmacol , vol.68 , Issue.6 , pp. 1529-1536
    • Rezai, K.1    Urien, S.2    Isambert, N.3
  • 154
    • 84899099079 scopus 로고    scopus 로고
    • Lapatinib-EMA.
    • Lapatinib-EMA. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/000795/WC500044957.pdf. Accessed 17 Jul 2013.
  • 155
    • 33745086350 scopus 로고    scopus 로고
    • Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
    • Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354(24):2542-51.
    • (2006) N Engl J Med , vol.354 , Issue.24 , pp. 2542-2551
    • Kantarjian, H.1    Giles, F.2    Wunderle, L.3
  • 156
    • 84879868783 scopus 로고    scopus 로고
    • Phase i study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: A National Cancer Institute Organ Dysfunction Working Group study
    • Shibata SI, Chung V, Synold TW, et al. Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res. 2013;19(13):3631-9.
    • (2013) Clin Cancer Res , vol.19 , Issue.13 , pp. 3631-3639
    • Shibata, S.I.1    Chung, V.2    Synold, T.W.3
  • 157
    • 84899095642 scopus 로고    scopus 로고
    • Sorafenib-EMA.
    • Sorafenib-EMA. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/000690/WC500027704.pdf. Accessed 16 Jul 2013.
  • 158
    • 79960151990 scopus 로고    scopus 로고
    • Population pharmacokinetic analysis of sorafenib in patients with solid tumours
    • 3162659
    • Jain L, Woo S, Gardner ER, et al. Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br J Clin Pharmacol. 2011;72(2):294-305.
    • (2011) Br J Clin Pharmacol , vol.72 , Issue.2 , pp. 294-305
    • Jain, L.1    Woo, S.2    Gardner, E.R.3
  • 159
    • 70350655546 scopus 로고    scopus 로고
    • Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
    • 2778527
    • Novello S, Scagliotti GV, Rosell R, et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer. 2009;101(9):1543-8.
    • (2009) Br J Cancer , vol.101 , Issue.9 , pp. 1543-1548
    • Novello, S.1    Scagliotti, G.V.2    Rosell, R.3
  • 160
    • 33749505836 scopus 로고    scopus 로고
    • Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial
    • Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329- 38.
    • (2006) Lancet , vol.368 , Issue.9544 , pp. 1329-1338
    • Demetri, G.D.1    Van Oosterom, A.T.2    Garrett, C.R.3
  • 161
    • 37249072373 scopus 로고    scopus 로고
    • A phase i and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period
    • Britten C, Kabbinavar F, Hecht J. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol. 2008;61:515-24.
    • (2008) Cancer Chemother Pharmacol , vol.61 , pp. 515-524
    • Britten, C.1    Kabbinavar, F.2    Hecht, J.3
  • 162
    • 84899119863 scopus 로고    scopus 로고
    • Vandetanib-EMA.
    • Vandetanib-EMA. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/002315/WC500123555.pdf. Accessed 16 Jul 2013.
  • 163
    • 23844544081 scopus 로고    scopus 로고
    • Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors
    • Holden SN, Eckhardt SG, Basser R, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol. 2005;16(8):1391-7.
    • (2005) Ann Oncol , vol.16 , Issue.8 , pp. 1391-1397
    • Holden, S.N.1    Eckhardt, S.G.2    Basser, R.3
  • 164
    • 33846844387 scopus 로고    scopus 로고
    • A phase i dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors
    • Tamura T, Minami H, Yamada Y, et al. A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol. 2006;1(9):1002-9.
    • (2006) J Thorac Oncol , vol.1 , Issue.9 , pp. 1002-1009
    • Tamura, T.1    Minami, H.2    Yamada, Y.3
  • 165
    • 79956029711 scopus 로고    scopus 로고
    • Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: An open-label, phase I, rising multiple-dose study
    • Zhang L, Li S, Zhang Y, et al. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study. Clin Ther. 2011;33(3):315-27.
    • (2011) Clin Ther , vol.33 , Issue.3 , pp. 315-327
    • Zhang, L.1    Li, S.2    Zhang, Y.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.